Loading...
|
Please use this identifier to cite or link to this item:
http://ntur.lib.ntu.edu.tw/handle/246246/170415
|
| Title: | A Novel Peptide Specifically Binding to Interleukin-6 Receptor (Gp80) Inhibits Angiogenesis and Tumor Growth |
| Authors: | 魏凌鴻;周佳宏;陳沛生;楊卿堯;陳祈安;蘇仁亮;郭明良;謝長堯
WEI, LIN-HUNG;CHOU, CHIA-HUNG;CHEN, PEI-SHENG;YANG, CHING-YAO;CHEN, CHI-AN;SU, JEN-LIANG;KUO, MIN-LIANG;HSIEH, CHANG-YAO |
| Contributors: | 腫瘤醫學部 |
| Date: | 2005 |
| Issue Date: | 2009-10-13T15:09:38Z |
| Abstract: | Experimental and clinical findings support the essential role of interleukin (IL)-6 in the pathogenesis of various human cancers and provide a rationale for targeted therapeutic investigations. A novel peptide, S7, which selectively binds to IL-6 receptor (IL-6R) chain (gp80 ) and broadly inhibits IL-6-mediated events, was identified using phage display library screening. The synthetic S7 peptide specifically bound to soluble IL-6R as well as cognate human IL-6R, resulting in a dose- dependent blockade of the interaction between IL-6 and IL-6R. S7 peptide prevents IL-6–mediated survival signaling and sensitizes cervical cancer cells to chemotherapeutic compounds in vitro. The in vitro analysis of antiangiogenic activity showed that S7 peptide substantially inhibits IL-6 –induced vascular endothelial growth factor-A expression and angiogenesis in different cancer cell lines. Furthermore, S7 peptide was bioavailable in vivo, leading to a significant suppression of IL-6–induced vascular endothelial growth factor–mediated cervical tumor growth in severe combined immunodeficient mice. These observations show the feasibility of targeting IL-6/IL-6R interaction using the small peptide and highlight its potential in the clinical applications. |
| Relation: | CANCER RESEARCH v.65 n.11 pp.4827-4835 |
| Appears in Collections: | [附設醫院腫瘤醫學部] 期刊論文
|
Files in This Item:
There are no files associated with this item.
|
All items in NTUR are protected by copyright, with all rights reserved.
|
